Type2 Diabetes
Conditions
Interventions
In addition to their baseline treatment, Pioglitazone 15 to 30 mg was orally administered once daily before or after breakfast.The dosage was adjusted according to the patient'
s sex, age and symptoms, up to the maximum daily dose of 45 mg.Concerning the use of pioglitazone in women or elderly patients, it was recommended to start treatment at 15 mg once daily. When it becam
Sponsors
Takeda Pharmaceutical Company Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Subjects whose HbA1c was 6.5% or more (2)Subjects who met at least two of the following conditions 1)Subjects with hypertension (those who met one of the following conditions) [1]Subjects who were diagnosed with hypertension and who had been on drug therapy [2]Subjects who had not received drug therapy and showed a systolic blood pressure of 140 mmHg or more ,or a diastolic blood pressure of 90 mmHg or more at rest in the sitting position. 2)Subjects with hyperlipidemia (including abnormality of lipid metabolism) (those who met one of the following conditions) [1]Subjects who were diagnosed with hyperlipidemia and who had been on drug therapy [2] Subjects who had not received drug therapy and showed a total cholesterol of 240 mg/dL or more, LDL-cholesterol of 160 mg/dL or more, or HDL-cholesterol of 40 mg/dL or less. 3)Subjects with a smoking habit (at least one cigarette/day) 4) Obesity (BMI 25 or more)
Exclusion criteria
Exclusion criteria: (1)Subjects who were diagnosed with type 1 diabetes mellitus (2)Subjects with a BMI of <22 and a fasting IRI of <5 mU/mL (3)Subjects who required insulin therapy to control the blood glucose of diabetes mellitus, or who were on insulin therapy (4)Subjects with a history of hepatic function disorder due to the use of thiazolidinediones (e.g., troglitazone and pioglitazone) (5)Subjects currently on pioglitazone therapy (6)Subjects who had cardiac failure or a history thereof (7)Subjects with cardiovascular disorders (those who met the following conditions) 1)Subjects with onset of myocardial infarction within 6 months 2)Subjects who received hospital treatment for acute coronary syndrome within 3 months 3) Subjects who underwent coronary artery bypass surgery or percutaneous transluminal coronary angioplasty within 6 months (8)Subjects with the complication of severe arrhythmia (9)Subjects with cerebrovasculardisorders [those with onset of cerebrovascular disorder (excluding TIA)] (10)Subjects who needed management of their blood glucose by insulin injection, due to severe infection, before or after operation, or serious traumatic injury (11)Subjects with scheduled coronary artery bypass surgery, percutaneous transluminal coronary angioplasty, or surgery for leg ischemia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to the onset of any of the following macrovascular events from the start of the treatment period (Week 0): [1]Death (endogenous) [2]Myocardial infarction (non-fatal) [3]Silent myocardial infarction [4]Acute coronary syndrome [5]Coronary intervention (percutaneous vascular intervention, coronary artery bypass surgery) [6]Cerebrovascular disorder (excluding TIA) [7]Lower limb (leg down to the ankle) amputation [8]Lower limb bypass surgery or angioplasty [9]Onset or worsening of angina pectoris [10]Arteriosclerosis obliterans | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in IMT, occurrence of adverse events (subjective and objective concurrent symptoms, abnormal changes in laboratory values) | — |
Countries
Japan
Outcome results
None listed